Does Retatrutide Cause Diarrhea? The Phase 2 Numbers in Context

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Retatrutide is investigational. FormBlends does not sell or supply it. Educational content only.
• Phase 2 retatrutide trial reported diarrhea in approximately 30 percent of participants at the 12 mg dose, with lower rates at lower doses.
• Diarrhea is dose-dependent and concentrated around dose-escalation periods.
• The rate appears somewhat higher than tirzepatide at comparable points but cross-trial comparisons require caution.
• Most patients see GI symptoms decline with stable maintenance dosing over time.

Direct answer

Yes. The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) reported diarrhea in approximately 30 percent of participants at the 12 mg maintenance dose, making it the second most common gastrointestinal adverse event after nausea (~50 percent). Rates were lower at lower doses, with most events clustering around dose-escalation periods. The pattern is consistent with the broader GLP-1 and dual/triple-agonist drug class, though retatrutide appears toward the higher end of the class at its higher doses.

Table of contents

1. What the Phase 2 trial actually measured
2. The dose-response relationship
3. Cross-trial comparison with tirzepatide and semaglutide
4. Why titration timing matters
5. The proposed mechanisms
6. When diarrhea is more than a side effect
7. How GLP-1-related diarrhea is typically managed
8. The dehydration cascade and electrolyte risk
9. Contrary view: are placebo rates higher than we think?
10. Decision framework
11. FAQ
12. Sources

What the Phase 2 trial actually measured

The Phase 2 retatrutide trial enrolled 338 adults with obesity randomized to placebo or one of four retatrutide maintenance doses (1, 4, 8, or 12 mg weekly) after dose escalation. Treatment continued for 48 weeks.

Adverse event reporting was patient-reported with investigator confirmation. Gastrointestinal events were the most common adverse event category, with a dose-dependent pattern across nausea, vomiting, diarrhea, and constipation. The 12 mg group had the highest event rates.

The publication reports approximately 50 percent nausea, 30 percent diarrhea, and 20 percent vomiting at the highest dose. Most events were rated mild or moderate; severe events were uncommon.

The dose-response relationship

The dose-response curve for diarrhea in the Phase 2 trial is approximately:

Dose	Diarrhea incidence (any-time during trial)
Placebo	~10%
1 mg	~13%
4 mg	~18%
8 mg	~24%
12 mg	~30%

Note that "any-time during trial" incidence describes whether a participant experienced the event at least once over 48 weeks, not the day-to-day prevalence. Point-prevalence is typically lower because events cluster around dose changes and resolve within days to weeks.

The dose-dependence is interpretable: more pharmacologic activity at the GLP-1, GIP, and glucagon receptors produces more downstream gastrointestinal effects.

Cross-trial comparison with tirzepatide and semaglutide

Trial-reported diarrhea rates at maximum doses across the GLP-1 and dual/triple-agonist class:

Drug	Trial	Max dose	Diarrhea rate	Placebo rate
Semaglutide	STEP 1	2.4 mg weekly	~31%	~16%
Tirzepatide	SURMOUNT-1	15 mg weekly	~19%	~9%
Retatrutide	Phase 2	12 mg weekly	~30%	~10%
Liraglutide	SCALE	3 mg daily	~21%	~10%

Cross-trial comparisons require caution: trial populations differ in baseline weight, comorbidities, and demographics; titration schedules vary; and definitions of "diarrhea" depend on patient self-report and investigator coding. The numbers are roughly in the same range, with retatrutide at the higher end at its tested maintenance doses.

Why titration timing matters

The Phase 2 retatrutide trial used a multi-week titration to allow gradual physiologic adaptation. Lower starting doses (0.5-2 mg) had GI event rates closer to placebo. Most events occurred during the first 2-4 weeks at a new dose level and declined as the body adapted.

This pattern is consistent across the GLP-1 and dual-agonist class. The Phase 3 TRIUMPH program is testing slower titration schedules in some arms specifically to characterize whether more gradual dose increases reduce the GI burden.

Practical implication: titration speed is a tunable variable. Patients with greater GI sensitivity may benefit from slower escalation; those who tolerate well can advance faster within the protocol envelope.

The proposed mechanisms

The mechanisms of GLP-1 receptor agonist-related diarrhea are not fully characterized but several contributors are proposed:

• Accelerated small bowel transit. Although gastric emptying is delayed, downstream small bowel motility may be altered, producing less complete nutrient and water absorption.
• Altered bile acid metabolism. GLP-1 agonism affects bile acid pool size and turnover, which can produce bile acid-related diarrhea in some individuals.
• Pancreatic effects. GLP-1 receptors are highly expressed in pancreatic beta cells; effects on exocrine pancreatic function are possible.
• Microbiome changes. Diet changes and motility changes both alter gut microbiome composition, which can have downstream effects on stool form.

For retatrutide specifically, the addition of glucagon receptor agonism may contribute additional GI effects beyond what GLP-1 and GIP agonism alone produce, but this is theoretical based on glucagon receptor biology rather than direct mechanistic study.

When diarrhea is more than a side effect

Most GLP-1-class diarrhea is mild and self-limited. Several patterns warrant clinical evaluation rather than symptomatic management:

• Severe or persistent diarrhea producing dehydration or electrolyte imbalance.
• Bloody stools, which suggest mucosal injury rather than functional disturbance.
• Diarrhea accompanied by severe abdominal pain, which could indicate pancreatitis.
• Diarrhea with persistent right-upper-quadrant pain, suggesting gallbladder pathology.
• Diarrhea with signs of bowel obstruction (vomiting, distension, no passage of stool or gas).

Approved GLP-1 medications have FDA labeling addressing pancreatitis, gallbladder disease, and bowel obstruction as recognized but uncommon serious adverse events. The same considerations apply by class for retatrutide.

How GLP-1-related diarrhea is typically managed

Clinical management of GLP-1-related diarrhea generally follows a stepwise approach:

1. Slow titration. Extending the time at each dose step before advancing.
2. Dietary modification. Smaller, lower-fat meals; avoiding sugar alcohols (sorbitol, xylitol); adequate hydration.
3. Symptomatic agents. Loperamide for short-term symptomatic relief when not contraindicated.
4. Dose reduction. Returning to the prior tolerated dose if GI symptoms persist at the higher dose.
5. Workup for alternative causes. Other infectious or structural causes of diarrhea should be considered if the pattern is atypical.

For retatrutide, these approaches are extrapolated from class experience because retatrutide-specific management protocols outside the clinical trial setting do not exist.

The dehydration cascade and electrolyte risk

Sustained diarrhea reduces fluid and electrolyte intake-output balance. The relevant clinical considerations:

• Hypovolemia, with risk of orthostasis and falls.
• Hypokalemia and hypomagnesemia, which can precipitate arrhythmias.
• Acute kidney injury from prerenal azotemia.
• In patients on diuretics, ACE inhibitors, or NSAIDs, the risk is amplified.

Older patients and those with comorbidities are most vulnerable. Clinicians often advise that patients hold ACE inhibitors and diuretics temporarily during acute GI illness.

Contrary view: are placebo rates higher than we think?

An important calibration point: placebo rates of diarrhea in obesity trials are not zero. The Phase 2 placebo rate was approximately 10 percent. This suggests that some fraction of "GLP-1-related" diarrhea in real-world use would have occurred anyway due to diet, comorbidity, or background prevalence.

The drug-attributable rate is the difference between active and placebo arms, which is closer to 20 percentage points at the highest retatrutide dose. The remaining background rate represents general GI variability in the obesity population.

This matters for individual interpretation. A patient experiencing diarrhea on retatrutide is not certain to have a drug-caused event; some occurrences will reflect baseline GI variability. Persistent and pattern-matched events are more likely drug-related.

Decision framework

If you are in a retatrutide trial:

• Report GI events to the study coordinator. Trial protocols include guidance on dose adjustment for symptoms.
• Hydration and dietary adjustments are first-line.

If you are using an approved GLP-1 medication:

• Discuss GI symptom management with your prescriber.
• Slower titration is an option for patients with significant GI sensitivity.

If you are evaluating GLP-1 therapy:

• The GI side effect profile is the most common reason for discontinuation in clinical trials.
• Most patients who tolerate the titration phase continue without ongoing severe symptoms.

If you experience severe or alarming symptoms:

• Bloody stools, severe abdominal pain, or signs of obstruction warrant urgent evaluation.

FAQ

Does retatrutide cause diarrhea? Yes. Phase 2 trial reported approximately 30 percent diarrhea at the 12 mg maintenance dose.

How common is it at lower doses? Substantially less. Rates near placebo at 1 mg and rising progressively through 4, 8, and 12 mg.

How does it compare to tirzepatide? Tirzepatide SURMOUNT-1 reported ~19 percent diarrhea at 15 mg. Retatrutide at its highest tested dose appears higher.

When does diarrhea happen? Most commonly during dose escalation; declines with stable maintenance dosing.

Why does it happen? Multiple mechanisms including altered transit, bile acid changes, and pancreatic effects.

Is it serious? Usually mild to moderate. Severe or persistent symptoms, blood in stool, or severe pain warrant evaluation.

How is it managed? Slower titration, dietary changes, hydration, and symptomatic treatment when appropriate.

Will it go away? Most patients see declining symptoms with continued stable dosing.

Is retatrutide FDA-approved? No. Retatrutide is investigational and not FDA-approved.

Related guides

• What Does Retatrutide Do? A Direct Look at the Phase 2 Numbers
• Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism
• Retatrutide and Diarrhea: What to Expect and How to Manage
• Retatrutide Diarrhea Management Tips
• Does Retatrutide Cause Muscle Loss? Lean Mass Data and What to Do About It
• Can Retatrutide Cause Cancer? Thyroid Risk, Class Effects, and What We Don't Know

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). NEJM. 2023;389:514-526.
2. Rosenstock J et al. Retatrutide in Type 2 Diabetes. The Lancet. 2023;402:529-544.
3. Jastreboff AM et al. Tirzepatide Once Weekly for Obesity. NEJM. 2022;387:205-216.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384:989-1002.
5. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM. 2015;373:11-22.
6. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
7. Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2024.
8. Zepbound (tirzepatide) prescribing information. Eli Lilly. Revised 2024.
9. Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Current Opinion in Endocrinology. 2019.
10. Nauck MA et al. Incretin hormones in obesity and diabetes. Molecular Metabolism. 2021;46:101102.
11. ClinicalTrials.gov. TRIUMPH Program Records. Accessed May 2026.
12. American Gastroenterological Association. Clinical Practice Update on Functional Diarrhea. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-licensed pharmacies. We do not manufacture, prescribe, or dispense medication.

Compounded Medication Notice. Compounded preparations are produced by 503A pharmacies for individual patients. They are not FDA-approved or reviewed through the FDA approval process and are not interchangeable with branded approved products. Retatrutide is not lawfully compoundable because it has not received FDA approval.

Results Disclaimer. Adverse event rates cited here come from controlled clinical trials. Real-world rates can differ. Individual experience varies widely.

Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda are registered trademarks of Novo Nordisk and Eli Lilly. Retatrutide is an investigational compound from Eli Lilly. FormBlends has no commercial relationship with these manufacturers.